|1.||Carlo, Gandolfo: 1 article (06/2013)|
|2.||Gianluigi, Lunardi: 1 article (06/2013)|
|3.||Patrizia, Garbati: 1 article (06/2013)|
|4.||Luisa, Perasso: 1 article (06/2013)|
|5.||Maurizio, Balestrino: 1 article (06/2013)|
|6.||Alessandro, Parodi: 1 article (06/2013)|
|7.||Enrico, Adriano: 1 article (06/2013)|
|8.||Oudman, Inge: 1 article (01/2011)|
|9.||Horjus, Deborah L: 1 article (01/2011)|
|10.||Brewster, Lizzy M: 1 article (01/2011)|
11/01/1996 - "Cyclocreatine (CCr) a CK substrate analog was shown to be cytotoxic to a broad spectrum of solid tumors. "
01/01/1995 - "The longest tumor-growth delays, up to 10 days, were produced by extended regimens of cyclocreatine. "
04/20/1994 - "Cyclocreatine was tested in this human tumor colony-forming assay at concentrations ranging from 0.067 to 20 mM against 128 tumor samples, 51 of which formed colonies in the assay and were considered evaluable. "
07/01/1993 - "Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors."
01/01/1995 - "Cyclocreatine in cancer chemotherapy."
10/01/1982 - "Dietary cyclocreatine offers no cerebral protection against hypoxia in mice."
10/01/1982 - "Cyclocreatine 1.0% in the absence of hypoxia caused significant mortality and decreased weight in survivors despite prophylactic antibiotic treatment. "
10/01/1982 - "Cyclocreatine 0.5% did not increase survival time during hypoxia (5% O2). "
06/01/2013 - "Cyclocreatine did not delay the disappearance of the evoked synaptic potentials during anoxia in hippocampal slices, unlike creatine which exerts a neuroprotective effect. "
04/01/1995 - "This study tests the hypothesis that the administration of cyclocreatine prior to global ischemia enhances recovery of cardiac function during reperfusion. "
12/01/1991 - "The concentration of tissue Pi was smaller in hearts from cyclocreatine-fed rats and appeared to increase more slowly during ischemia. "
11/01/1990 - "We tested the hypothesis that if ischemia is important for the formation of NCF from the myocardium, then blocking (or delaying) ischemic changes with cyclocreatine should inhibit the release of NCF. "
05/15/1987 - "In contrast, breast muscle of chicks fed either 1 or 0.5% cyclocreatine still contained 28 and 19 mumol/g of cyclocreatine-P, respectively, after 1 h of ischemia; after 2 h of ischemia, the respective cyclocreatine-P values were 20 and 13 mumol/g. "
07/01/1989 - "During ischemia, the heart of control rats developed a rigor-like increase in tonic pressure (ischemic contracture) not seen in the heart of cyclocreatine-fed rats (22 versus 1 mm Hg, p less than 0.01). "
07/01/1995 - "Our results suggest the possible use of cyclocreatine in the treatment of prostatic carcinoma."
07/01/1995 - "Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells."
01/01/1996 - "Cyclocreatine transport and cytotoxicity in rat glioma and human ovarian carcinoma cells: 31P-NMR spectroscopy."
07/01/1995 - "Results reported herein indicate an increased level of creatine kinase activity in human prostate carcinoma cell lines and inhibitory effects of cyclocreatine alone and in combination with adriamycin on the growth of these cells in vitro and in vivo, in immune-deprived mice. "
05/01/1996 - "The cytotoxicity and effect on cellular energy parameters of AG-17, lonidamine and cyclocreatine were examined in four human tumor cell lines: MCF-7 breast carcinoma, SW2 small cell lung carcinoma, A2058 melanoma and A2058-055, a subline of A2058 transfected with the creatine kinase gene. "
|6.||Creatine Kinase (Creatine Phosphokinase)
|7.||Adenosine Triphosphate (ATP)
|10.||Mitochondrial Form Creatine Kinase
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)